Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

A Novel Treatment for Malarial Infections

Posted Jun 15 2010 5:00pm

Description of Invention:
The inventions described herein are antimalarial small molecule inhibitors of the plasmodial surface anion channel (PSAC), an essential nutrient acquisition ion channel expressed on human erythrocytes infected with malaria parasites. These inhibitors were discovered by high-throughput screening of chemical libraries and analysis of their ability to kill malaria parasites in culture. Two separate classes of inhibitors were found to work synergistically in combination against PSAC and killed malaria cultures at markedly lower concentrations than separately. These inhibitors have high affinity and specificity for PSAC and have acceptable cytotoxicity profiles. Preliminary in vivo testing of these compounds in a mouse malaria model is currently ongoing.

Applications:
Treatment of malarial infections

Advantages:
  • Novel drug treatment for malarial infections
  • Synergistic effect of these compounds on PSAC


Development Status:
In vitro and in vivo data can be provided upon request.

Inventors:
Sanjay A Desai (NIAID)


Patent Status:
HHS, Reference No. E-202-2008/0
PCT, Application No. PCT/US09/50637 filed 15 Jul 2009


Relevant Publication:
  1. M Kang, G Lisk, S Hollingworth, SM Baylor, SA Desai. Malaria parasites are rapidly killed by dantrolene derivatives specific for the plasmodial surface anion channel. Mol. Pharmacol. 2005 Jul;68(1):34-40. [ PubMed abs ]
  2. SA Desai, SM Bezrukov, J Zimmerberg. A voltage-dependent channel involved in nutrient uptake by red blood cells infected with the malaria parasite. Nature. 2000 Aug 31;406(6799):1001-1005. [ PubMed abs ]


Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The NIAID Office of Technology Development is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize antimalarial drugs that target PSAC or other parasite-specific transporters. Please contact Dana Hsu at 301-496-2644 for more information.


Portfolios:
Infectious Diseases
Infectious Diseases - Therapeutics
In-vivo Data
In-vitro Data



For Additional Information Please Contact:
Kevin Chang Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: changke@mail.nih.gov
Phone: 301-435-5018
Fax: 301-402-0220


Ref No: 1827

Updated: 06/2010

Post a comment
Write a comment:

Related Searches